Clinical Trial Update: Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of CPX-351 (Vyxeos) in individuals under 22 with secondary myeloid neoplasms; study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Neoplasms

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Myeloid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING